There are 412 resources available
1082O - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)
Presenter: Isabella Glitza
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
LBA15 - Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Presenter: Antonio Passaro
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
2395P - Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC)
Presenter: Akshay Sood
Session: Poster session 24
1367P - Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453
Presenter: Barend Sikkema
Session: Poster session 19
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20
LBA93 - EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
Presenter: Ying Liu
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast